Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin® as 1st Line Therapy (Post-HERMINE Study)

Hoffmann-La Roche0 个研究点目标入组 220 人开始时间: 2010年2月最近更新: 2016年2月22日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Hoffmann-La Roche
入组人数: 220
主要终点: Median Overall Survival

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•Female patient, >/= 18 years of age
•Metastatic breast cancer
•1st-line treatment with Herceptin initiated in 2002
•Included in pharmaco-epidemiologic HERMINE study

排除标准

•Patient died before scheduled follow-up visit (March 2005)

结局指标

主要结局

Median Overall Survival

时间窗: Up to 7 years

The time between the first infusion of trastuzumab and the date of death from any cause. Participants who were still alive at the end of the post-HERMINE study or lost to follow-up were censored at the last date they were known to be alive.

次要结局

Median Time to Progression(Up to 7 years)
Median Time to Progression-Free Survival(Up to 7 years)
Prognostic Factors for Overall Survival(Up to 7 years)
Prognostic Factors For Time to Progression(Up to 7 years)
Median Treatment Duration and the Duration of Exposure to Trastuzumab(Up to 7 years)

研究者

发起方

Hoffmann-La Roche

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

3 期

Combined Study - Phase 3b MenB Long Term Persistence in AdolescentsInfections, Meningococcal

NCT02446743GlaxoSmithKline531

已完成

2 期

Phase II study of R-CHOP and R-high-dose MTX therapy for IVLBCL (PRIMEUR-IVL)Intravascular large B-cell lymphoma

JPRN-UMIN000005707IVL study group in Japan38

已完成

2 期

Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced HepatocarcinomaAdvanced Hepatocarcinoma

NCT01418729Hospital Donostia216

已完成

3 期

Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic XerosisUremic Xerosis

NCT01084148Orfagen237

尚未招募

不适用

Retrospective analyze of survival rate, complications and quality of live after use of an Extracorporeal Life Support System (ECLS)All Patients who received ECLS are included no matter which health condition they had before. But mostly they had a heart attack or a cardiogenic shock or similar.

DRKS00015685niversitätsklinikum Freiburg400